Home » EU

Thought Leadership

CBPartners’ EU Centre of Excellence has the global expertise to engage with business unit leaders on cross-market strategy. Our in-house local expertise and experience is paired with a strong network of healthcare decision-makers across the region.

Showing 5 of 20 posts
eu in pills
April 14, 2020 | Blogs

The COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe

Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.

Tumour case study
March 24, 2020 | Blogs

Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.

Gene editing case study
March 24, 2020 | Blogs

Genome Editing: An Introduction

A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.

us fist and eu palm
January 29, 2020 | Blogs

Strategic Thinking: The Global Drug Launch Pricing Dilemma

Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies. Product launches vary based on geography; when comparing the USA to EU, access outcomes can vary significantly based on whether or not the pivotal trial design has been optimized for each region.